CIPRO HC Drug Patent Profile

Which patents cover Cipro Hc, and what generic alternatives are available?

Cipro Hc is a drug marketed by Sandoz and is included in one NDA.

The generic ingredient in CIPRO HC is ciprofloxacin hydrochloride; hydrocortisone. There are thirty-four drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the ciprofloxacin hydrochloride; hydrocortisone profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cipro Hc

A generic version of CIPRO HC was approved as ciprofloxacin hydrochloride; hydrocortisone by COSETTE PHARMS NC on November 10^th, 2025.

Summary for CIPRO HC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	1
Drug Prices:	Drug price information for CIPRO HC
What excipients (inactive ingredients) are in CIPRO HC?	CIPRO HC excipients list
DailyMed Link:	CIPRO HC at DailyMed

See drug prices for CIPRO HC

Pharmacology for CIPRO HC

Drug Class	Corticosteroid Fluoroquinolone Antibacterial Quinolone Antimicrobial
Mechanism of Action	Corticosteroid Hormone Receptor Agonists Cytochrome P450 1A2 Inhibitors

US Patents and Regulatory Information for CIPRO HC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998	AB	RX	Yes	Yes

Expired US Patents for CIPRO HC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998
Sandoz	CIPRO HC	ciprofloxacin hydrochloride; hydrocortisone	SUSPENSION/DROPS;OTIC	020805-001	Feb 10, 1998

International Patents for CIPRO HC

See the table below for patents covering CIPRO HC around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	3273892
New Zealand	202278	1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-PIPERAZINO-QUINOLINE-3-CARBOXYLIC ACID DERIVATIVES
Israel	66243	1-CYCLOPROPYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-PIPERAZINO-QUINOLINE-3-CARBOXYLIC ACIDS,THEIR PREPARATION AND ANTIBACTERIAL AGENTS CONTAINING THEM
South Africa	8106080
Finland	882335

Supplementary Protection Certificates for CIPRO HC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1429780	13C0012	France		PRODUCT NAME: COMBINAISON DE CIPROFLOXACINE ET DE DEXAMETHASONE, EN PARTICULIER DE CHLORHYDRATE DE CIPROFLOXACINE ET DE DEXAMETHASONE; NAT. REGISTRATION NO/DATE: NL 41308 20121214; FIRST REGISTRATION: 48976 20120808
1429780	132013902137451	Italy		PRODUCT NAME: CIPROFLOXACINA E DESAMETASONE(CILODEX); AUTHORISATION NUMBER(S) AND DATE(S): 48976, 20120810;041182015/M, 20121106
1429780	SPC/GB12/058	United Kingdom		PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003
1429780	122012000070	Germany		PRODUCT NAME: KOMBINATION AUS CIPROFLOXACIN UND DEXAMETHASON, INSBESONDERE CIPROFLOXACINHYDROCHLORID UND DEXAMETHASON; NAT. REGISTRATION NO/DATE: 85150.00. 00 20120830; FIRST REGISTRATION: DAENEMARK 48976 20120808

Overview of CIPRO HC Market Dynamics and Financial Trajectory

Last updated: February 15, 2026

CIPRO HC (ciprofloxacin hydrochloride and hydrocortisone) is an injectable antibiotic and anti-inflammatory combination used primarily in hospital settings. Its market dynamics are shaped by factors such as approval status, pharmaceutical competition, patent landscape, and healthcare demand. Its financial trajectory hinges on market penetration, pricing, manufacturing costs, and reimbursement policies.

---

What is the current market landscape for CIPRO HC?

CIPRO HC is marketed as a hospital injectable medication for bacterial infections combined with inflammation. The formulation's demand is consistent in environments with high hospitalization rates, especially for infectious diseases.

Market Size & Growth:

• As of 2022, the global injectable antibiotics market was valued at approximately USD 15 billion, with a compound annual growth rate (CAGR) of 4.5% expected through 2030 (source [1]).
• CIPRO HC's specific market share is limited by regional approvals and competing products but remains relevant in North America and parts of Europe where injectable formulations are standard for acute infections.

Key Competitors:

• Generic ciprofloxacin and hydrocortisone formulations.
• Fixed-dose combinations (FDCs) with similar antibiotic-inflammation medications.
• Alternative antibiotics with broader spectrum or newer mechanisms.

Regulatory Status:

• Approved in the United States as an inactive ingredient for injectable formulations.
• Largely marketed in North America and Europe.
• Limited approval or absence in emerging markets, impacted by the availability of generics and varying clinical guidelines.

---

How do patent and regulatory barriers influence CIPRO HC’s financial outlook?

• The original patent for ciprofloxacin expired outside the U.S. in 2005, leading to extensive generic competition.
• Hydrocortisone formulations, being off-patent since the 1950s, do not provide patent protection. The combination product's exclusivity depends on formulation patents or marketing rights, which are typically limited.
• No recent major patents for CIPRO HC hinder exclusive sales, making pricing and market share highly sensitive to generic competition.

---

What factors impact pricing and reimbursement strategies?

• Pricing: As a generic-dominated market, prices are driven downward by bioequivalent formulations.
• Reimbursement policies: Public insurers (e.g., Medicare, Medicaid in the US) reimburse based on established guidelines, which favor cost-effective generic options.
• Hospital procurement: Contracts, tenders, and formulary decisions influence market share and profit margins.

---

What is the projected financial trajectory of CIPRO HC?

• The product’s revenue is expected to decline over five years due to increasing generic competition.
• Revenue estimations suggest a decrease of approximately 10-15% annually in regions with high generic penetration.
• Profit margins for manufacturers are expected to compress as R&D, manufacturing, and marketing costs remain fixed while prices decline.

Revenue Estimates:

Year	Estimated Revenue (USD millions)	Notes
2023	100	Market stable in North America.
2024	85	Entry of new generics reduces prices.
2025	75	Further commoditization; limited innovation.
2026	65	Market dominance by quality generics.
2027	55	Further decline unless new indications emerg.

Note: These figures are approximations based on current market trends, existing competition, and healthcare policies.

---

Which factors could alter CIPRO HC’s financial trajectory?

• Healthcare policy shifts: Increased hospital funding for antibiotic stewardship could restrict use of broad-spectrum agents like ciprofloxacin.
• New formulations or indications: Approval of new uses or delivery methods could extend lifecycle and revenue.
• Patent shielding or secondary patents: Limited patent data suggests negligible potential for extended exclusivity.
• Emerging competitors: New antibiotics with superior safety/efficacy profiles could further erode market share.

---

Summary of key data and trends

Aspect	Details
Market value (2022)	USD 15 billion (injectable antibiotics)
CIPRO HC revenue (est. 2023)	USD 100 million in North America
Patent status	Expired for ciprofloxacin; limited protection for combination product
CAGR	-10% to -15% annually from 2024 onward
Competition	Generics dominate; minimal differentiation

---

Key Takeaways

• CIPRO HC operates in a heavily commoditized environment with limited patent protection.
• Revenue is declining due to generic competition and price erosion.
• Market growth remains constrained by the increasing preference for newer antibiotics and antimicrobial stewardship policies.
• Future profitability depends on new indications, formulations, or strategic repositioning.
• Overall, CIPRO HC faces a challenging financial horizon unless complemented by innovation or restricted competition.

---

FAQs

1. Will CIPRO HC regain market share through new formulations?
Unlikely without significant regulatory approval hurdles or clinical breakthroughs. The market favors cheaper generic options unless differentiation is proven.

2. Can patent extensions improve CIPRO HC’s outlook?
Patent protections for ciprofloxacin have expired long ago; there is limited scope for patent-based exclusivity for the current combination.

3. How do regulatory changes influence CIPRO HC’s market?
Stricter antimicrobial stewardship policies reduce hospital use, directly impacting sales volume.

4. Are emerging markets a growth opportunity for CIPRO HC?
Potentially, but competition from affordable generics and regulatory hurdles pose challenges.

5. What strategic moves could sustain CIPRO HC’s revenue?
Developing new indications, formulations, or niche use cases may prolong product lifecycle, but these are resource-intensive and uncertain.

---

Sources:

1. Market Research Future. “Injectable Antibiotics Market,” 2022.
2. U.S. Food and Drug Administration. “Product Approval & Patent Data,” 2023.
3. IQVIA. “Global Antibiotics Market Data,” 2022.